sub:assertion {
d:DB00748 v:identifier "DB00748" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB00748" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB00748> ;
dv:drugbank-id "APRD00765" , "DB00748" ;
dv:x-atc <
http://bio2rdf.org/atc:R06AA08> ;
dv:x-bindingdb <
http://bio2rdf.org/bindingdb:50240487> ;
dv:x-cas <
http://bio2rdf.org/cas:486-16-8> ;
dv:x-chebi <
http://bio2rdf.org/chebi:3398> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:2466> ;
dv:x-kegg <
http://bio2rdf.org/kegg:C06871> ;
dv:x-ndc <
http://bio2rdf.org/ndc:0525-6748-01> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA164746898> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:2564> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:46506787> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Carbinoxamine> ;
dct:description "Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state \"do not use\" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks."@en ;
dct:identifier "drugbank:DB00748" ;
dct:title "Carbinoxamine"@en ;
a dv:Drug ;
rdfs:label "Carbinoxamine [drugbank:DB00748]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB00748> , <
http://www.drugs.com/cdi/carbinoxamine-maleate.html> , <
http://www.rxlist.com/cgi/generic3/rondecsyr.htm> .
}